Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes

Debbie L. Hay, George Christopoulos, Arthur Christopoulos, David R. Poyner, and Patrick M. Sexton

School of Biological Sciences, University of Auckland, Auckland, New Zealand (D.L.H.); Howard Florey Institute (G.C., P.M.S.) and Department of Pharmacology (A.C.), University of Melbourne, Victoria, Australia; and School of Life and Health Sciences, Aston University, Birmingham, United Kingdom (D.R.P.)

Received October 21, 2004; accepted February 3, 2005

ABSTRACT

Calcitonin (CT) receptors dimerize with receptor activity-modifying proteins (RAMPs) to create high-affinity amylin (AMY) receptors, but there is no reliable means of pharmacologically distinguishing these receptors. We used agonists and antagonists to define their pharmacology, expressing the CT_(a) receptor alone or with RAMPs in COS-7 cells and measuring cAMP accumulation. Intermedin short, otherwise known as adrenomedullin 2, mirrored the action of α CGRP, being a weak agonist at CT_(a), AMY_{2(a)}, and AMY_{3(a)} receptors but considerably more potent at AMY_{1(a)} receptors. Likewise, the linear calcitonin gene-related peptide (CGRP) analogs (Cys(ACM)^{2,7})h α CGRP and (Cys(Et)^{2,7})h α CGRP were only effective at AMY_{1(a)} receptors, but they were partial agonists. As previously observed in COS-7 cells, there was little induction of the AMY_{2(a)} receptor phenotype; thus, AMY_{2(a)} was not exam-

The peptides typically designated as calcitonin (CT) peptide family members include CT gene-related peptide (CGRP), amylin (AMY), and adrenomedullin (AM) (Poyner et al., 2002), although an assortment of related peptides has recently been identified, including intermedin (IMD), also known as AM2 (Katafuchi et al., 2003; Roh et al., 2004; Takei et al., 2004). Although only weakly homologous in terms of amino acid sequence, several common ined further in this study. The antagonist peptide salmon calcitonin₈₋₃₂ (sCT₈₋₃₂) did not discriminate strongly between CT and AMY receptors; however, AC187 was a more effective antagonist of AMY responses at AMY receptors, and AC413 additionally showed modest selectivity for AMY_{1(a)} over AMY_{3(a)} receptors. CGRP₈₋₃₇ also demonstrated receptor-dependent effects. CGRP₈₋₃₇ more effectively antagonized AMY at AMY_{1(a)} than AMY_{3(a)} receptors, although it was only a weak antagonist of both, but it did not inhibit responses at the CT_(a) receptor. Low CGRP₈₋₃₇ affinity and agonism by linear CGRP analogs at AMY_{1(a)} are the classic signature of a CGRP₂ receptor. Our data indicate that careful use of combinations of agonists and antagonists may allow pharmacological discrimination of CT_(a), AMY_{1(a)}, and AMY_{3(a)} receptors, providing a means to delineate the physiological significance of these receptors.

features are shared, including an N-terminal ring structure that is the key to agonist activity. Nonetheless, the similarity in peptide structure leads to promiscuity for many of these peptides across their cognate receptors. Numerous biological activities have been attributed to these peptides. CT, for example, is involved in bone homeostasis (Sexton et al., 1999). AMY is likely to be involved in nutrient intake and regulating blood glucose levels (Cooper, 1994). CGRP and AM are both potent vasodilators, with AM necessary for vascular integrity (Hinson et al., 2000; Shindo et al., 2001; Brain and Grant, 2004). As with many other peptides, significant advances in understanding the physiological, pathophysiological, and clinical potential of CT family members are hampered by a lack of selective pharmacological agents that can be used to define function. Progress has been particularly slow for the CT peptide family because, until recently, the

This work was supported by the National Health and Medical Research Council of Australia (grants 145702 and 299810), the Ian Potter Foundation Neuropeptide Laboratory and the University of Auckland Staff Research Fund, the Auckland Medical Research Foundation, and Lottery Health Commission (New Zealand). P.M.S. and A.C. are Senior Research Fellows of the National Health and Medical Research Council. D.R.P. was supported by the British Heart Foundation (Grant PG/03/079/15278).

Article, publication date, and citation information can be found at $\ensuremath{\mathsf{http://molpharm.aspetjournals.org}}.$

doi:10.1124/mol.104.008615.

ABBREVIATIONS: CT, calcitonin; CGRP, calcitonin gene-related peptide; AMY, amylin; AM, adrenomedullin; IMD, intermedin; GPCR, G protein coupled receptor; CL, calcitonin receptor-like receptor; RAMP, receptor activity modifying protein; CT_(a), calcitonin receptor; rAMY, rat amylin; IMDS, intermedin short; BSA, bovine serum albumin; ALPHA, amplified luminescent proximity homogenous assay; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; HA, hemagglutinin; PBS, phosphate-buffered saline; hCT, human calcitonin; AC187, SC[acetyl-(Asn³⁰,Tyr³²)-calcitonin₈₋₃₂].

molecular nature of the cognate receptors for AMY, CGRP, and adrenomedullin was unknown.

There is now some clarity regarding the nature of the receptor that probably mediates many of the effects of CGRP. It consists of a complex between a seven-transmembrane protein belonging to the secretin family of G protein-coupled receptors (GPCRs), the CT receptor-like receptor (CL), with receptor activity modifying protein (RAMP)1 (McLatchie et al., 1998). When these proteins are coexpressed, classic CGRP₁-like pharmacology is observed (McLatchie et al., 1998; Hay et al., 2004). However, if CL is instead coexpressed with either of the two other RAMP family members, RAMP2 or RAMP3, adrenomedullin is recognized most effectively (McLatchie et al., 1998). Thus, RAMPs act as pharmacological switches. It was soon realized that the function of RAMPs may be much broader, and there are now several examples of secretin family GPCRs with which these proteins are likely to interact (Christopoulos et al., 1999, 2003; Leuthauser et al., 2000).

It is noteworthy that RAMPs have a strong interaction with the CT receptor, the closest relative to CL (Christopoulos et al., 1999). Together, RAMPs and the CT receptor generate receptors with high affinity for AMY, with the precise nature of these receptors depending on the CT receptor splice variant and cellular background (Tilakaratne et al., 2000). To our knowledge, there have been no other reports of a distinct molecular entity capable of responding to AMY with such high affinity. It is noteworthy that early attempts to clone the AMY receptor usually produced the CT receptor; thus, it is likely that CT receptor/RAMP complexes mediate at least some of the effects of AMY in vivo, although this has yet to be directly tested. It is crucial to note that there is no reliable means of distinguishing CT from AMY receptors or AMY receptor subtypes pharmacologically in functional systems. Although comprehensive binding and agonist-interaction analyses have been performed, there has been no critical analysis of the way that antagonists interact with these receptors. This type of information may allow the different biological effects of AMY and related peptides to be attributed to distinct receptor subtypes. It can also provide a basis for the rational design of more selective agents. This is important because an AMY analog (Pramlintide) has now reached late-stage development for glycemic control in diabetic patients, illustrating the clinical importance of this peptide.

Therefore, in this study, we have sought to address this issue by transfecting the CT receptor $[CT_{(a)};$ Poyner et al., 2002] with or without RAMPs into COS-7 cells that do not endogenously express phenotypically significant levels of RAMPs, CT receptors, or CL. We have identified several key aspects of pharmacology that relate to the way that AMY and its related peptides have historically been reported to act in tissues.

Materials and Methods

Materials. Human AM, human adrenomedullin₂₂₋₅₂ (AM₂₂₋₅₂), rat AMY₈₋₃₇, human α CGRP, human α CGRP₈₋₃₇, human β CGRP, and acetyl-(Asn³⁰,Tyr³²)-calcitonin₈₋₃₂ (AC187) were purchased from Bachem (Bubendorf, Switzerland). Salmon calcitonin₈₋₃₂ [sCT₈₋₃₂] was from Peninsula Laboratories (Belmont, CA), and human Tyr⁰ α CGRP, (Cys(Et)^{2,7})- α CGRP, (Cys(Acm)^{2,7})- α CGRP, and rat AMY (rAMY) were from Auspep (Parkville, Australia). AC413 was a generous gift from Dr. Andrew Young (Amylin Pharmaceuticals Inc., La Jolla, CA). Human CT was obtained from the American Peptide Co., Inc. (Sunnyvale, CA). IMD short (IMDS) was a generous gift from Dr. Teddy Hsu (Stanford University School of Medicine, Stanford, CA; Roh et al., 2004). Peptide sequences are detailed in Fig. 1. Bovine serum albumin (BSA) and 3-isobutyl-1-methylxanthine were from Sigma-Aldrich (St. Louis, MO), and amplified luminescent proximity homogenous assay (ALPHA)-screen cAMP kits were purchased from PerkinElmer Life and Analytical Sciences (Boston, MA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), and HEPES were from Invitrogen (Carlsbad, CA). Cell culture plastic ware was manufactured by NUNC A/S (Roskilde, Denmark), and Metafectene was purchased from Scientifix (Cheltenham, VIC, Australia). ¹²⁵I-Labeled goat anti-mouse IgG was obtained from PerkinElmer Life and Analytical Sciences. Na-¹²⁵I (100 mCi/ml) was supplied by MP Biomedicals (Irvine, CA). ¹²⁵I-Salmon CT (specific activity, 700 Ci/mmol) was iodinated in-house as described previously (Findlay et al., 1980). N-Succinimidyl 3-94-hydroxy,5,-[125]iodophenyl propionate (Bolton-Hunter reagent; 2000 Ci/mmol) was from Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK). ¹²⁵I-Rat amylin (specific activity, 2000 Ci/mmol) was iodinated by the Bolton-Hunter method and purified by reverse phase high-performance liquid chromatography as described previously (Bhogal et al., 1992). All other reagents were of analytical grade.

Expression Constructs. Double hemagglutinin (HA) epitopetagged human $CT_{(a)}$ receptor was prepared as described previously (Pham et al., 2004). This receptor is the Leu⁴⁴⁷ polymorphic variant of the receptor (Kuestner et al., 1994). Human RAMP1, RAMP2, and RAMP3 and human CL receptor were a gift from Dr. Steven Foord (McLatchie et al., 1998).

Cell Culture and Transfection. COS-7 cells were subcultured as described previously (Zumpe et al., 2000). One day before transfection, COS-7 cells were seeded into 25- or 75-cm² cell culture flasks at high density to achieve 90 to 100% confluence for transfection the next day. The cells were then transfected using Metafectene according to the manufacturer's instructions, with the following amounts of DNA: For 25-cm² flasks, 1.25 μ g of receptor DNA [CT_(a) or CL] and 1.9 μ g of RAMP or pcDNA3 DNA; for 75-cm² flasks, 3.8 μ g of receptor DNA, and 5.7 μ g of RAMP or pcDNA3 DNA. The transfection mix was removed after 16-h incubation, and the cells were recovered in complete media (DMEM with 5% FBS) for 8 h. The cells were then serum-starved for a further 16 h to minimize basal cAMP levels.

Measurement of cAMP Production. Cells transfected with CT_(a) or CL plus pcDNA3, RAMP1, -2, or -3 were harvested approximately 40 h after transfection. The cells were counted and diluted to 20,000 cells per 10 μ l and incubated, mixing for at least 30 min in serum and phenol red-free DMEM containing 0.1% (w/v) BSA and 1 mM 3-isobutyl-1-methylxanthine (stimulation buffer). Agonist and antagonist dilutions were prepared in stimulation buffer and added to white 384-well plates, either alone or in combination, to a total volume of 10 μ l. After incubation of cells with stimulation buffer, 20,000 cells were added per well in a volume of 10 μ l. The plates were centrifuged very briefly to ensure thorough mixing of these small volumes. The plates were then incubated for 30 min at 37°C. Drugstimulated receptor activity was terminated by the addition of 20 μ l of lysis buffer [0.3% (v/v) Tween 20, 5 mM HEPES, 0.1% (w/v) BSA in water, pH 7.4]. After addition of lysis buffer, the plates were again centrifuged briefly to ensure thorough mixing. The cAMP in the lysed cells was assayed in the same wells using ALPHA-screen assay kits. A cAMP standard curve was included in each assay. In brief, cAMP was measured with acceptor and donor beads that were prepared in lysis buffer and added to the plates according to the manufacturer's instructions. After overnight incubation in the dark, the plates were read with an ALPHA-screen protocol on a Fusion plate reader (PerkinElmer Life and Analytical Sciences).

Radioligand Binding. When harvested for cAMP assay (see above), the same transfected COS-7 cells were also seeded into 24-well culture plates at a density of approximately 250,000 cells per

well. These cells were then assayed for receptor binding to either ¹²⁵I-rAMY or ¹²⁵I-sCT the next day (16 h later). Cells were initially washed with 500 μ l of phosphate-buffered saline (PBS) and incubated for 30 min at 37°C in 500 μ l of binding buffer [FBS-free DMEM with 0.1% (w/v) BSA]. Wells contained either 50 pM ¹²⁵I-sCT or 100 pM ¹²⁵I-rAMY. Nonspecific binding levels were determined by competing with 10⁻⁷ M sCT or 10⁻⁶ M rAMY, respectively. Cells were then washed twice with 500 μ l of PBS and were solubilized with 0.5 ml of 0.5 M NaOH with the cell lysate counted for γ -radiation using a PerkinElmer γ -counter (COBRA Auto-gamma, Model B5010; 75% efficiency).

For full-curve competition binding experiments, cells in 75-cm² flasks were transfected for 5 h using Metafectene, with 3.7 μ g of CT_(a) and either 5.2 μ g of pcDNA3, RAMP1, or RAMP3 DNA. The cells were allowed to recover for 16 h and then harvested and seeded at around 80 to 90% confluence into 48-well plates. These were then allowed to adhere and recover for a further 16 h. Competition binding was performed for 2 h at room temperature. Each well contained 225 μ l of DMEM + 0.1% BSA, 200 pM ¹²⁵I-rAMY, and 25 μ l of competing peptide (10^{-12} – 10^{-7} M) or buffer control. Cells were washed once with PBS, lysed, and counted as described above.

Measurement of Cell Surface Expression by Antibody Binding. As for binding assays, at the time of harvesting for cAMP assay, transfected COS-7 cells were plated into 24-well plates and later assayed for cell-surface expression of the HA-tagged receptor. Cells were rinsed twice with 0.5 ml of binding buffer [50 mM Tris-HCl, pH 7.7, 100 mM NaCl, 5 mM KCl, 2 mM CaCl₂, and 1% (w/v) BSA, adjusted to pH 7.7 with HCl] followed by addition of 2 μ g of HAspecific mouse antibody in 250 μ l of binding buffer to each well. Cells were incubated for 3 h at 4°C, with gentle agitation. Cells were then

AGONISTS

rAMY8-37

CGRP8-37

AM22-52

[8]

[8]

[22]

QRL

н

Q K

R L

Ν

G

L

QI

А

A

VRSSNN

s

RSGGV

YQF

rinsed three times with binding buffer, and 125 I-labeled goat antimouse IgG (diluted to give 200 pM/250 μ l per well) was added to the cells. The cells were incubated for a further 3 h at 4°C and then rinsed three times with binding buffer. Cells were solubilized with 0.5 ml of 0.5 M NaOH, and the cell lysate was counted for γ -radiation. Nonspecific binding was determined from the wells that received 125 I-labeled goat anti-mouse IgG but not the anti-HA primary antibody.

Data Analysis and Statistics. Data were analyzed using Prism 4.02 (GraphPad Software Inc., San Diego, CA). In each assay, the quantity of cAMP generated was calculated from the raw data using a cAMP standard curve. For agonist responses, concentration-effect curves were fitted to a four-parameter logistic equation (Motulsky and Christopoulos, 2003).

For calculation of antagonist potency, agonist concentrationresponse curves in the absence and presence of antagonist were globally fitted to the following equation using Prism (Motulsky and Christopoulos, 2004):

$$\label{eq:Response} {\rm Response} = E_{\min} + \frac{(E_{\max} - E_{\min})[A]^{n_{\rm H}}}{[A]^{n_{\rm H}} + \left(10^{-{\rm pEC}_{50}} \! \left[1 + \left(\frac{[B]}{10^{-{\rm pA}_2}}\right)^{\rm s}\right]\right)^{n_{\rm H}}}$$

where $E_{\rm max}$ represents the maximal asymptote of the concentrationresponse curves, $E_{\rm min}$ represents the lowest asymptote of the concentration-response curves, pEC₅₀ represents the negative logarithm of the agonist EC₅₀ in the absence of antagonist, [A] represents the concentration of the agonist, [B] represents the concentration of the antagonist, $n_{\rm H}$ represents the Hill slope of the agonist curve, s represents the Schild slope for the antagonist, and pA₂ represents

hCT rAmy hαCGRP Tyr ⁰ -hαCGRP (Cys(Et) ^{2.7})-hαCGRP (Cys(Acm) ^{2.7})-hαCGRP hβCGRP IMDS hAM	[1] C G N L S T C A T C A T Q R L A N F L U [17] [1] K C N T A T C A T Q R L A N F L U [17] [1] A C D T A T C V T H R L A G L L S [17] [0] Y A C D T A T C V T H R L A G L L S [17] [1] Y A C D T A T C V T H R L A G L L S [17] [1] A C D T A T C V T H R
hCT rAmy hαCGRP Tyr ⁰ -hαCGRP (Cys(Et) ^{2.7})-hαCGRP (Cys(Acm) ^{2.7})-hαCGRP hβCGRP IMDS hAM	$ \begin{bmatrix} 18 \end{bmatrix} K F \\ \hline S S N N L G P V L P P T N V G S N T Y \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G V V K N N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G G M V K S N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G G M V K S N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G G M V K S N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G G M V K S N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G G M V K S N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G G M V K S N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G G M V K S N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G G M V K S N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S G G G M V K S N F V P T N V G S S K A F \\ \begin{bmatrix} 18 \end{bmatrix} R S S G G G M V K S N F V P T N V F N V F S S F H S Y \\ \begin{bmatrix} 18 \end{bmatrix} R S S F \\ \begin{bmatrix} 18 \end{bmatrix} R \\ \begin{bmatrix} 18 \end{bmatrix} R S F \\ \begin{bmatrix} 18 \end{bmatrix} R \\ \begin{bmatrix} 18 \\ R \end{bmatrix} R \\ \begin{bmatrix} 18 \\ R$
ANTAGONISTS sCT8-32 AC187 AC413	[8] VLGKLSQELHK LQTYPRTNTGSGTP-NH2 [32] [8] Ac- VLGKLSQELHK LQTYPRTNTGSNTY-NH2 [32] [8] ATQRLANFLVR LQTYPRTNVGANTY-NH2 [32]

Fig. 1. Peptide sequences and alignment. Sequences were aligned according to the ClustalV methods (PAM250) using the MegAlign program from DNAstar Inc. (Madison, WI). For agonist peptides, residues that match the consensus CGRP sequence are boxed (top). For antagonist peptides, residues that match the overall consensus are boxed (bottom). The location of the disulfide-linked cysteines in agonist peptides is also indicated. The exception to this are the analogs $Cys(Et)^{2,7}$ - α CGRP and $Cys(Acm)^{2,7}$ - α CGRP where the disulfide linkage has been blocked. Modification to these cysteines is indicated by bold boxes.

L G P V L P P T N V G S N

V K N

TDKDKDNV

NF

A

V P

Ν

Т

G

PRSKISPQGY

Y -NH₂

-NH₂

-NH₂ [52]

A F

к

S

[37]

[37]

the negative logarithm of the concentration of antagonist that shifts the agonist EC_{50} by a factor of 2. Parallelism of agonist concentration-response curves in the presence of antagonist relative to the absence of antagonist was assessed by F-test, which compared curve fits where the $n_{\rm H}$ parameter was shared across each family of curves to fits where each curve within a family was allowed its own Hill slope factor. The F-test was similarly used to determine whether the Schild slope was significantly different from unity within a given data set. In the majority of instances, this was not the case, and thus all curves were refitted with the Schild slope constrained to a value of 1; under these conditions, the resulting estimate of pA_2 represents the $pK_{\rm B}$.

In all cases, potency and affinity values were estimated as logarithms (Christopoulos, 1998). Data shown are the mean \pm S.E.M. Comparisons between mean values were performed by unpaired *t* tests or one-way analysis of variance, as appropriate. Unless otherwise stated, values of p < 0.05 were taken as statistically significant.

Results

COS-7 cells were chosen for transfection studies as they have been shown to lack phenotypically significant levels of




Fig. 2. Cell surface expression of CT_(a) protein, in COS-7 cells transiently transfected with CT_(a) alone or CT_(a) in the presence of either RAMP1 [AMY_{1(a)}], RAMP2 [AMY_{2(a)}], or RAMP3 [AMY_{3(a)}], measured by binding of anti-HA antibody to the 2xHA epitope incorporated at the N terminus of the receptor. Primary antibody binding is detected by incubation of a ¹²⁵I-labeled goat anti-mouse IgG antibody as described under *Materials and Methods*. In untransfected or mock-transfected cells the level of binding was <15% of binding seen in CT_(a)-transfected cells. Data are expressed as a percentage of the binding of ¹²⁵I-antibody to cells expressing the CT_(a) protein in the absence of RAMP cotransfection. Data are from 10 independent experiments with duplicate repeats.

TABLE 1

Agonist potencies (pEC_{50} values) for stimulation of cAMP accumulation at human CT and AMY receptors Data are presented as mean \pm S.E.M. Values in parentheses represent the number of individual experiments analyzed.

endogenous RAMPs, CT receptors, and CL (Hay et al., 2003). Without significant background expression of such receptor components, defined receptor subtypes can be accurately compared.

Agonist Pharmacology. The approach taken to generate a detailed pharmacological analysis of the molecularly defined AMY receptors was to compare the effects of all available antagonists against the major agonists that were capable of eliciting reliable receptor activation. Therefore, we initially examined agonist-induced cAMP responses in cells transfected with CT_(a) alone or in combination with individual RAMPs to assess the relative agonist activation profiles of the receptors defined as $CT_{(a)}$, $AMY_{1(a)}$, $AMY_{2(a)}$, and $AMY_{3(a)}$, respectively. In most experiments, cell surface expression of the $\mathrm{CT}_{(\mathrm{a})}$ was confirmed by binding of an anti-HA antibody to the epitope tag incorporated into the N terminus of the receptor (Fig. 2). In addition, in some experiments ¹²⁵I-sCT binding was also performed and confirmed that similar levels of the receptor protein were expressed at the cell surface (data not shown). Expression of the AMY receptor phenotype was confirmed by concomitant ¹²⁵I-rAMY binding (data not shown).

As shown in Table 1 and in accordance with previous results, hCT displayed equivalent high potency in cells transfected with $\text{CT}_{(a)}$ or $\text{AMY}_{1(a)}$ receptors but had $\sim \! 10 \text{-fold lower}$ potency at AMY_{3(a)} receptors (p < 0.05; n = 6). In contrast, rAMY and the CGRPs had low potency at the CT_(a) receptor and exhibited ~100-fold increased potency at the $AMY_{1(a)}$ receptor. As seen previously in this cellular background, preliminary analysis of radioligand binding and cAMP response indicated very little induction of $AMY_{2(a)}$ phenotype with pEC₅₀ values for rAMY at this receptor equivalent to that seen with $CT_{(a)}$ alone (data not shown; Christopoulos et al., 1999; Tilakaratne et al., 2000). rAMY had high potency at the AMY_{3(a)} receptor, but the CGRPs showed only modest increases in potency (<10-fold) at this receptor. At all receptor phenotypes, Tyr^{0} -h α CGRP was weaker than unmodified h α CGRP, but it exhibited similar modulation of potency to α and β -CGRP at AMY_{1(a)} receptors.

IMD displays efficacy at CL/RAMP-based receptors (Roh et al., 2004; Takei et al., 2004). We examined the interaction of the short form of this peptide, IMDS, with CT and AMY receptors and compared it with the behavior of the peptide at CGRP and AM receptors. IMDS had low potency at $CT_{(a)}$ and $AMY_{2(a)}$ receptors and displayed a similar increase in potency at $AMY_{1(a)}$ (~40-fold) and $AMY_{3(a)}$ (<10 fold) receptors,

	$CT_{(a)}$	$AMY_{1(a)}$	$AMY_{3(a)}$
hCT	8.99 ± 0.1 (8)	$8.93 \pm 0.09 (7)$	8.02 ± 0.22 (7)
rAMY	6.95 ± 0.18 (8)	9.12 ± 0.16 (10)	8.63 ± 0.09 (7)
$h\alpha CGRP$	6.80 ± 0.05 (5)	8.70 ± 0.17 (6)	7.60 ± 0.17 (6)
Tyr^{0} -h α CGRP	<6 (2)	7.55 ± 0.17 (7)	<6 (3)
hβCGRP	7.18 ± 0.22 (2)	9.16 ± 0.18 (9)	7.67 ± 0.23 (6)
$(Cys(Et)^{2,7})h\alpha CGRP$	<6 (3)	$7.79 \pm 0.14 \ (5)^a$	<6 (6)
$(Cys(ACM)^{2,7})h\alpha CGRP$	<6 (3)	$7.46 \pm 0.06 \ (4)^a$	<6 (6)
hĂM	6.73 ± 0.45 (3)	6.48 ± 0.28 (4)	6.89 ± 0.51 (3)
IMDS	6.53 ± 0.09 (6)	$8.07 \pm 0.19 \ (6)^b$	7.12 ± 0.19 (6)

^{*a*} Note that these CGRP analogues were weak partial agonists at this receptor, with E_{max} values of 47.9 ± 5.4 and 22.8 ± 6% for (Cys(Et)^{2.7})h\alpha CGRP and (Cys(ACM)^{2.7})h\alpha CGRP, respectively. These values were generated by comparing the curve maximum asymptotes of the h\alpha CGRP analogs with that for h\alpha CGRP itself (set at 100%), which was used as the reference full agonist for these experiments.

 $^{b}E_{\text{max}}$ values for IMDS were equivalent to those of h α CGRP assayed in parallel.

as seen for the CGRPs (Fig. 3; Table 2). This contrasts with the interaction of IMDS at CGRP and AM receptors assayed in the same cellular background where IMDS displayed similar high efficacy at all three receptors but differed from the activity of h α CGRP at these receptors, which only had high potency at the CGRP₁ receptor (Fig. 3; Table 2).

The linear CGRP analogs $(Cys(Et)^{2,7})-\alpha CGRP$ and $(Cys(Acm)^{2,7})$ - $\alpha CGRP$ have been used to subclassify CGRP receptors into CGRP₁ and CGRP₂ receptors (Dennis et al., 1990, 1991; Poyner et al., 2002). Because AMY receptors can also function as high-affinity CGRP receptors, it was of interest to assess the potency of the linear CGRP analogs at CT and AMY receptors. Both analogs had very low potency and efficacy at CT_(a), AMY_{2(a)}, and AMY_{3(a)} receptors, but they displayed moderate potency at the $AMY_{1(a)}$ receptor (Table 1; Fig. 4A). However, both analogs were only partial agonists at the latter receptor exhibiting $\% E_{\rm max}$ responses of 47.9 \pm 5.4 and 22.8 \pm 6.0, respectively, for $(Cys(Et)^{2,7})$ - $\alpha CGRP$ and $(Cys(Acm)^{2,7})$ - $\alpha CGRP$. At the $CGRP_1$ receptor, both analogs displayed high potency, pEC₅₀ of 9.4 \pm 0.12 (n = 5) and 9.08 \pm 0.63 (n = 4) for (Cys(Et)^{2,7})- α CGRP and (Cys(Acm)^{2,7})- α α CGRP, respectively, similar to unmodified h α CGRP [9.51 ± 0.14 (n = 5)], but they were again partial agonists. However,

 $(\text{Cys(Et)}^{2,7})$ - α CGRP was considerably more efficacious than $(\text{Cys(Acm)}^{2,7})$ - α CGRP with % E_{max} values of 83.5 ± 7.2 and 8.1 ± 2.1, respectively (Fig. 4B).

TABLE 2

Comparison of IMDS and h α CGRP potency for stimulation of cAMP accumulation at human CT, AMY, CGRP, and AM receptors Values are presented as mean \pm S.E.M.


1			
Receptor	Agonist	pEC_{50}	n
$CT_{(a)}$	IMDS	6.53 ± 0.09	6
(4)	$h\alpha CGRP$	6.80 ± 0.04	5
AMY _{1(a)}	IMDS	$8.07 \pm 0.19^{*}$	6
1(u)	$h\alpha CGRP$	8.70 ± 0.17	10
$AMY_{2(a)}$	IMDS	6.25 ± 0.26	6
	$h\alpha CGRP$	7.24 ± 0.19	5
AMY _{3(a)}	IMDS	$7.12\pm0.19^{\dagger}$	6
0(u)	$h\alpha CGRP$	7.60 ± 0.17	6
$CGRP_1$	IMDS	8.71 ± 0.13	8
-	$h\alpha CGRP$	9.47 ± 0.19	6
AM_1	IMDS	8.10 ± 0.04	4
-	$h\alpha CGRP$	6.39 ± 0.10	4
AM_2	IMDS	8.69 ± 0.13	5
-	$h\alpha CGRP$	6.87 ± 0.13	3

* P < 0.05 versus $CT_{(a)}$, $AMY_{2(a)}$, and $AMY_{3(a)}$ receptors. † P < 0.05 versus $CT_{(a)}$, $AMY_{1(a)}$, and $AMY_{2(a)}$ receptors.

А

В

Α 80 AMY_{3(a)} AMY_{2(a)} [cAMP] nM 60 AMY_{1(a)} 40 CT_(a) 0 20 0--12 -11 -10 -9 -8 -7 -6 Log [IMDS] M В 40 CGRP cAMP] nM 30 AM₁ AM₂ 20 10 0. -12 -11 -10 -9 -8 -6 Log [IMDS] M






Fig. 3. Induction of cAMP accumulation by IMDS in COS-7 cells transiently transfected with $CT_{(a)}$ -based receptor phenotypes (A) and CL-based receptor phenotypes (B). For CGRP and AM receptors, the response across receptors probably represents different levels of receptor expression. The E_{\max} for IMDS and h α CGRP was equivalent for all. The graph is of a representative experiment, with triplicate repeats, of at least six independent experiments.

Fig. 4. Induction of cAMP accumulation at AMY_{1(a)} (A) or CGRP₁ (B) receptors by linear CGRP analogs. haCGRP (closed squares), (Cys(Et)^{2.7})- α CGRP (\bullet), and (Cys(Acm)^{2.7})- α CGRP (open circles). pEC₅₀ and E_{max} values, respectively, at the CGRP₁ receptor were haCGRP, 9.51 ± 0.14, 100% (n = 5); (Cys(Et)^{2.7})- α CGRP, 9.40 ± 0.12, 83.54 ± 7.19% (n = 5); and (Cys(Acm)^{2.7})- α CGRP, 9.08 ± 0.63, 8.08 ± 2.09% (n = 4). The graph is of a representative experiment, with triplicate repeats, of at least four independent experiments. pEC₅₀ and E_{max} values for peptides at the AMY_{1(a)} receptor are detailed in Table 1.

Antagonist Pharmacology. N-Terminally truncated analogs of CT and related peptides have traditionally been used as "specific" antagonists of the primary receptors at which they interact. However, the specificity of interaction across the range of CT and AMY receptor phenotypes has not been systematically addressed. We have therefore assessed the relative effectiveness of these peptide antagonists and a number of chimeras of sCT₈₋₃₂ and rAMY (Fig. 1) as antagonists of CT_(a), AMY_{1(a)}, and AMY_{3(a)} receptors. Antagonist studies were not performed at the AMY_{2(a)} receptor because of the weak AMY phenotype we observe in COS-7 cells.

Of the peptides examined, sCT₈₋₃₂ was the most effective antagonist with a $pK_{\rm B}$ of ~8 across all receptors examined. It did not display significant selectivity, with a similar $pK_{\rm B}$ observed for CT_(a), AMY_{1(a)}, and AMY_{3(a)} receptors, for each of the agonists (Table 3; Figs. 5, A and E, 6, A and E, and 7, A and E), although there was a weak trend for lower affinity at AMY_{1(a)} receptors with either rAMY or the CGRPs as agonists (Fig. 8A).

In contrast, the CGRP₁ receptor antagonist CGRP₈₋₃₇ was selective for AMY receptors over CT receptors (Fig. 8B), with no antagonism of agonist responses at CT receptors with concentrations of antagonist up to 10^{-5} M (Table 3; Fig. 5, B and F). However, CGRP₈₋₃₇ was only a weak antagonist at AMY_{1(a)} and AMY_{3(a)} receptors with $pK_{\rm B}$ values of <7 (Table 3; Figs. 6, B and F, and 7, B and F). With AMY as agonist, CGRP₈₋₃₇ exhibited weak selectivity for AMY_{1(a)} over AMY_{3(a)} receptors, although this did not reach statistical significance (*t* test; *p* = 0.11) in the current study. There was an apparent agonist-dependent component to antagonism by CGRP₈₋₃₇, with no effect seen at any of the receptors when hCT was used as the agonist (Table 3; Figs. 5B, 6B, and 7B).

In support of the weak effect of AM at these receptors (Table 1), AM_{22-52} , an antagonist of AM receptors, had no effect at either CT or AMY receptors (Table 3). Confirmation of the integrity of AM_{22-52} was obtained in experiments with AM_2 receptors, where this peptide is known to be an antagonist (data not shown; Hay et al., 2003). rAMY₈₋₃₇ was almost without activity, exhibiting only very weak antagonist activity at $AMY_{1(a)}$ receptors, and only when rAMY was the agonist (Table 3).

The peptide chimeras of rAMY and sCT₈₋₃₂, AC187 and AC413, each had affinity for $CT_{(a)}$, $AMY_{1(a)}$, and $AMY_{3(a)}$ receptors but displayed selectivity between receptor phenotypes (Table 3; Fig. 8, C and D). AC187 was \sim 10-fold more potent an antagonist of $AMY_{1(a)}$ receptors compared with $CT_{(a)}$ receptors when rAMY was used as the agonist (Table 3; Figs. 5G, 6G, and 8C). Likewise, AC187 was more potent at $AMY_{3(a)}$ receptors over $CT_{(a)}$ receptors when rAMY was the agonist (Table 3; Figs. 5G, 7G, and 8C), but no significant difference was seen between AMY_{1(a)} and AMY_{3(a)} receptors (Fig. 8C). As seen with CGRP₈₋₃₇, there was an apparent agonist-dependent effect observed with the antagonist potency of AC187 when hCT was the agonist, because no significant change in AC187 potency was seen across the three receptor types (Table 3; Fig. 8C). Equivalent antagonist behavior was observed for AC413 when hCT was the agonist, with no difference in antagonist potency between CT_(a), AMY_{1(a)}, and AMY_{3(a)} receptors (Table 3; Figs. 5D, 6D, 7D, and 8D). However, additional receptor-dependent and agonist-dependent behavior was seen for AC413. For each of the receptors, AC413 was more potent when rAMY was the agonist versus when hCT was the agonist (Table 3; Figs. 5, 6, 7, H versus D, and 8D), although this was not significant at the $AMY_{3(a)}$ receptor. AC413 also seemed to discriminate between $AMY_{1(a)}$ versus $AMY_{3(a)}$ receptors when rAMY was used as the agonist, being more effective at $AMY_{1(a)}$ (Fig. 8D).

In competition for $^{125}I\text{-rAMY}$ binding, $s\text{CT}_{8\text{-}32},$ AC187, and AC413 each displayed high affinity at both $\text{AMY}_{1(a)}$ and

TABLE 3

 $pK_{\rm B}$ values for antagonists in antagonizing agonist-induced stimulation of cAMP accumulation at human CT and AMY receptor phenotypes Values are presented as mean \pm S.E.M.

Antagonist & Receptors Agonist pK _B	n
sCT ₈₋₃₂	
$CT_{(-)}$ hCT 8.17 ± 0.17	7
$CT_{(a)}^{(a)}$ rAMY 8.22 ± 0.26	7
$AMY_{1(a)}$ hCT 7.95 ± 0.16	7
$AMY_{1(2)}$ rAMY 7.78 ± 0.13	11
$AMY_{1(a)}^{(a)} h\alpha CGRP \qquad 7.80 \pm 0.17$	11
$AMY_{1(a)}^{I(a)} h\beta CGRP \qquad 7.68 \pm 0.18$	12
$AMY_{1(a)}^{r(a)} Tyr^{0}-h\alpha CGRP 7.61 \pm 0.17$	4
$AMY_{3(a)}^{(a)}$ hCT 7.87 ± 0.25	6
$AMY_{3(a)}^{3(a)}$ rAMY 7.92 ± 0.19	6
AC187	
$CT_{(a)}$ hCT 7.15 ± 0.23	7
$CT_{(a)}$ rAMY 6.89 ± 0.25	7
$AMY_{1(a)}$ hCT 7.30 ± 0.11	7
$AMY_{1(a)}$ rAMY 8.02 ± 0.18	7
$h\alpha CGRP$ 7.86 ± 0.20	11
$h\beta CGRP$ 7.85 ± 0.26	4
AMY _{1(a)} Tyr ⁰ -h α CGRP 7.73 ± 0.27	4
AMY ₃₍₂₎ hCT 7.37 ± 0.33	6
$AMY_{3(a)}$ rAMY 7.68 ± 0.22	5
AC413	
$CT_{(a)}$ hCT 6.94 ± 0.13	7
$CT_{(a)}$ rAMY 7.48 ± 0.17	7
$AMY_{1(a)}$ hCT 7.11 ± 0.27	5
$AMY_{1(a)}$ rAMY 7.92 ± 0.23	4
$AMY_{1(\alpha)}$ haccord $haccord = 0.24$	10
$h\beta CGRP$ 7.25 ± 0.21	2
AMY _{1(a)} Tyr ⁰ -h α CGRP 7.44 ± 0.67	2
$AMY_{2(0)}$ hCT 6.83 ± 0.27	8
$AMY_{3(a)}^{3(a)}$ rAMY 7.10 ± 0.14	8
$h\alpha CGRP_{8-37}^{(a)}$	
$CT_{(a)}$ hCT <5	5
$CT^{(a)}_{(a)}$ rAMY <5	4
$AMY_{1(a)}$ hCT <5	7
AMY ₁₍₂₎ rAMY 6.62 ± 0.13	11
$AMY_{1(a)}^{I(a)} h\alpha CGRP \qquad 6.79 \pm 0.24$	9
$AMY_{1(a)}^{I(a)} h\beta CGRP \qquad 6.78 \pm 0.13$	14
$AMY_{1(a)}^{(a)} Tyr^{0}-h\alpha CGRP \qquad 6.56 \pm 0.4$	6
$AMY_{3(a)}^{1(a)}$ hCT ≤ 5	8
$AMY_{3(a)}^{3(a)}$ rAMY 6.17 ± 0.26	7
$rAMY_{8-37}$	
$CT_{(a)}$ hCT <5	2
$CT_{(a)}$ rAMY <5	2
$AMY_{1(a)}$ hCT <5	4
$AMY_{1(2)}$ rAMY 5.59 ± 0.24	3
$AMY_{1(\alpha)}$ hac GRP N.D.	-
$h\beta CGRP$ N.D.	
$\operatorname{AMY}_{1(a)}^{1(a)}$ $\operatorname{Tyr}^{0}-h\alpha \operatorname{CGRP}$ N.D.	
$AMY_{2(n)}$ hCT <5	3
$\begin{array}{ccc} \text{AMY}_{3(a)} & \text{rAMY} & <5 \\ \text{AMY}_{3(a)} & \text{rAMY} & <5 \end{array}$	4
hAM ₂₂ z ₂	-
$CT \leq hCT \leq 5$	1
$CT_{(a)}$ rAMY <5	1
$AMY_{1(z)}$ hCT <5	3
$AMY_{1(z)}$ $rAMY$ ≤ 5	3
$h\alpha CGRP < 5$	1
$\begin{array}{ccc} \text{AMY}_{1(a)} & \text{haccurr} & <5 \\ \text{AMY}_{1(a)} & \text{h}\beta\text{CGRP} & <5 \end{array}$	1
$\operatorname{AMY}_{1(a)}^{1(a)}$ $\operatorname{Tyr}^{0}-h\alpha \operatorname{CGRP}$ N.D.	-
$\begin{array}{ccc} \text{AMY}_{1(a)} & \text{Fyr-fuccult} & \text{A.D.} \\ \text{AMY}_{3(a)} & \text{hCT} & <5 \end{array}$	4
	-
$\operatorname{AMY}_{3(a)}^{A,M,Y}$ $\operatorname{AMY}_{3(a)}^{A,M,Y}$ $\operatorname{AMY}^{A,G,M,Y}$ <5	4

N.D., not done; <5, antagonist caused no significant shift of the agonist concentration effect curve at concentrations of $10^{-5}~M.$




Fig. 5. Representative antagonist curves at $CT_{(a)}$ receptors: $sCT_{8.32}$ (A and E), $CGRP_{8.37}$ (B and F), AC187 (C and G), and AC413 (D and H) with hCT (A–D) or rAMY (E–H) as agonist. Control (agonist alone) (\bullet), + 10⁻⁸ M antagonist (\triangle); + 10⁻⁷ M antagonist (\bigtriangledown), + 10⁻⁶ M antagonist (\diamond), and + 10⁻⁵ M antagonist (\bigcirc).




Fig. 6. Representative antagonist curves at AMY_{1(a)} receptors: sCT_{8-32} (A and E), $CGRP_{8-37}$ (B and F), AC187 (C and G), and AC413 (D and H) with hCT (A–D) or rAMY (E–H) as agonist. Control (agonist alone) (\bullet), + 10^{-8} M antagonist (\triangle), + 10^{-7} M antagonist (\bigtriangledown), + 10^{-6} M antagonist (\diamond), and + 10^{-5} M antagonist (\bigcirc).

 $AMY_{3(a)}$ receptors, whereas $CGRP_{8-37}$ had lower affinity for both receptors (Table 4). However, consistent with their lack of antagonist potency at AMY receptors, $rAMY_{8-37}$ and hAM_{22-52} both exhibited very low affinity (Table 4).

Discussion

Many factors alter the potency of agonists at GPCRs; affinity and intrinsic efficacy are receptor-dependent, whereas receptor density and G protein-coupling efficiency are system-dependent (Kenakin, 1997; Armour et al., 1999). In this study, we examined the effect of agonists and antagonists on CT and AMY receptors expressed at similar levels in the same cellular background to reduce system-dependent variables and to allow comparison of relative affinity and intrinsic efficacy of the agents used (Armour et al., 1999).

As seen previously (Christopoulos et al., 1999; Muff et al., 1999), coexpression of $CT_{(a)}/RAMP1$ led to receptors that were potently stimulated by rAMY and CGRP, whereas CT_{(a}/RAMP3 expression generated receptors potently stimulated by rAMY but only moderately by CGRP. In contrast, CT_(a) expressed alone responded weakly to peptides aside from hCT. hCT potently stimulated cAMP production in COS-7 cells coexpressing $CT_{(a)}$ /RAMP1 but was right-shifted (10-fold) in cells expressing $CT_{(a)}/RAMP3$. In all cases, antagonist pK_B values were equivalent across receptors when hCT was used as the agonist, suggesting that hCT stimulation of cAMP is via the same receptor $[CT_{(a)}]$, regardless of cotransfected RAMPs. This implies that hCT has only very low affinity for AMY receptors. This was consistent with competition binding studies where hCT had low affinity at both AMY_{1(a)} and AMY_{3(a)} receptors (Table 4; Christopoulos et al., 1999). Unlike CL, $\rm CT_{(a)}$ expresses at the cell surface in a RAMP-independent manner (Lin et al., 1991; Kuestner et al., 1994), so cotransfection with RAMP leads to mixed populations of "free" and heterodimerized receptor. The reduced hCT potency at $AMY_{3(a)}$ is consistent with a marked decrease in the level of "free" $CT_{(a)}$, contrasting with the lack of modulation of hCT efficacy seen with RAMP1 cotransfection. This implies that CT_(a) has a stronger interaction with RAMP3 than RAMP1 and is supported by the consistent reduction in CT potency with RAMP3 that is not seen with RAMP1 (Armour et al., 1999; Christopoulos et al., 1999; Muff et al., 1999; Tilakaratne et al., 2000; Kuwasako et al., 2004) and also that only RAMP3 is able to induce an AMY receptor phenotype in melanophores (Armour et al., 1999). However, it is also possible that hCT has lower efficacy at AMY_{3(a)} versus AMY_{1(a)} receptors.

Initial studies with IMDS indicated that it could interact, with similar potency, with CGRP and AM receptors (Roh et al., 2004). We have confirmed this observation. Its efficacy was equivalent to that of h α CGRP, but there were marked differences in the relative potency of these two peptides for individual CL/RAMP combinations. However, at CT_(a)-based receptors, the activity of IMDS tracked that of h α CGRP. This suggests that the IMDS binding interface at CT_(a)-based receptors is similar to that of the CGRPs and contrasts to its mode of interaction with CL/RAMP receptors. In our COS-7 cell background, the overall potency of IMDS was weaker at CT-based receptors than at CL/RAMP receptors, suggesting that the physiological target of IMDS is more likely to be the latter receptor family. During the preparation of this manuscript, a study examining the effect of IMD at CT_(a)-based




Fig. 7. Representative antagonist curves at $AMY_{3(a)}$ receptors: sCT_{8-32} (A and E), $CGRP_{8-37}$ (B and F), AC187 (C and G), and AC413 (D and H) with hCT (A–D) or rAMY (E–H) as agonist. Control (agonist alone) (\bullet), + 10^{-8} M antagonist (\triangle), + 10^{-7} M antagonist (\bigtriangledown), + 10^{-6} M antagonist (\diamond), and + 10^{-5} M antagonist (\bigcirc).

receptors in COS-7 cells was published, with similar findings to ours (Takei et al., 2004).

Unlike agonist behavior, antagonist potency is viewed as a receptor-dependent variable, and so antagonists are the preferred tool for defining receptor subtypes (Christopoulos and El-Fakahany, 1999). We have delineated the pharmacology of $CT_{(a)}$ -based receptors through functional analysis of the effects of N-terminally truncated analogs of CT and related peptides, including chimeras between rAMY and sCT₈₋₃₂.

 $\rm sCT_{8-32}$ had high affinity for all three receptor subtypes but discriminated little between them. However, the small, non-significant decrease in affinity against AMY versus CT receptors was similar to $\rm sCT_{8-32}$ behavior at $\rm CT_{(a)}$ and $\rm AMY_{3(a)}$ receptors in melanophores where higher affinity at $\rm CT_{(a)}$ receptors was observed (Armour et al., 1999).

 $CGRP_{8-37}$ was highly selective for AMY receptors over CT receptors and was weakly selective for $AMY_{1(a)}$ over $AMY_{3(a)}$ receptors, mirroring the effects of $\alpha CGRP$ at these receptors.

However, its potency against AMY receptors was much lower than against CGRP₁ (CL/RAMP1) receptors expressed in the same system [$pK_B 9.34 \pm 0.38 (n = 5)$; D. L. Hay, manuscript in preparation]. As such, it is a useful research tool for investigation of receptor subtypes but only in combination with a range of other antagonists that can distinguish between CGRP-responsive receptors.

AC187 had high affinity for AMY receptors and was ~10fold selective for these receptors over CT receptors. AC187 has only low affinity for CGRP₁ receptors (Howitt and Poyner, 1997; D. L. Hay, manuscript in preparation) and therefore is useful for discriminating between CL- and CT-based receptors. However, low selectivity between AMY versus CT receptors limits its usefulness.

AC413 provided the first evidence for selectivity between $AMY_{1(a)}$ and $AMY_{3(a)}$ receptors with pK_B values of 7.92 and 7.10, respectively, against rAMY. Although the difference is small, the peptide may guide the design of more specific




Fig. 8. Distribution of $pK_{\rm B}$ values for the antagonists sCT₈₋₃₂ (A), CGRP₈₋₃₇ (B), AC187 (C), and AC413 (D). Comparisons were performed using an unpaired *t* test. The number of individual experiments used to calculate the $pK_{\rm B}$ values are indicated in parentheses. The boxed values for $pK_{\rm B}$ of AC187 for the agonists rAMY, α CGRP, and β CGRP at the AMY_{1(a)} receptor were all significantly different from the indicated comparator.

antagonists. The different pK_B values of AC413 for rAMY versus hCT at CT_(a) receptors are difficult to reconcile with simple competitive antagonism, where the nature of the agonist should not alter the pK_B . There may be differences in the mode of binding of rAMY and hCT at this receptor. It is possible that although partially overlapping, the binding sites of hCT and rAMY at the CT_(a) receptor are significantly different, allowing an allosteric interaction; such interactions are often characterized by apparent agonist-dependent antagonist $pK_{\rm B}$ values (Christopoulos and Kenakin, 2002). Unlike AC187, which has only two amino acids of rAMY substituted into the sCT₈₋₃₂ backbone, AC413 is also homologous to rAMY over residues 8 to 18 (Fig. 1) and so may interact with higher affinity at the site occupied by rAMY versus that occupied by hCT. On the other hand, each of the agonists may provide a unique receptor conformation, leading to alteration in system-dependent activity of the receptor that is manifest as differential antagonist affinity. However, we believe this is less likely, as such changes could be expected to alter affinity of other antagonists.

In contrast to the N-terminally truncated peptides already described, rAMY₈₋₃₇ was essentially without antagonist activity at any of the receptors, consistent with its low affinity in competition binding studies (Table 4; Aiyar et al., 1995). Nonetheless, this peptide can antagonize some AMY-induced responses (Wang et al., 1993; Ye et al., 2001).

Subdivision of CGRP receptors was first proposed by Dennis et al. (1990, 1991), based primarily on the observation that CGRP₈₋₃₇ exhibits high-affinity antagonism for only CGRP₁ receptors. On the other hand, linear analogs of $h\alpha CGRP$ [most commonly (Cys(Acm)^{2,7})- $\alpha CGRP$] have higher potency at CGRP₂ receptors. However, the range of reported values for these peptides is extremely broad (Poyner et al., 2002; Hay et al., 2004), and differences seen in functional assays are not apparent in competition binding assays (Rorabaugh et al., 2001). Although it is now generally accepted that CL/RAMP1 represents the CGRP₁-receptor phenotype (Poyner et al., 2002), the molecular identity of the receptor(s) giving rise to CGRP₂ pharmacology is obscure. Recent work with $(Cys(Acm)^{2,7})-\alpha CGRP$ and $(Cys(Et)^{2,7})-\alpha CGRP$ α CGRP has provided some evidence that AMY receptors may contribute to CGRP₂ pharmacology (Kuwasako et al., 2004). Taken with this latter work, the current study identifies a

TABLE 4

Peptide affinity (pIC $_{\rm 50}$ values) for inhibition of $^{125}\text{I-rAMY}$ binding to human AMY receptors

Values are presented as mean \pm S.E.M. for three independent experiments, each with three replicates.

	$AMY_{1\left(a\right)}$	AMY _{3(a)}
hCT	=6	≤ 6
rAMY	8.76 ± 0.06	8.60 ± 0.09
$h\alpha CGRP$	8.00 ± 0.08	6.97 ± 0.55
$Tyr^{0}-h\alpha CGRP$	6.85 ± 1.05	6.73 ± 1.46
$h\beta CGRP$	8.80 ± 0.08	7.71 ± 0.07
$(Cys(Et)^{2,7})h\alpha CGRP$	7.19 ± 0.06	6.96 ± 0.74
$(Cys(ACM)^{2,7})h\alpha CGRP$	6.87 ± 1.08	6.45 ± 0.10
hAM	< 6	< 6
IMDS	6.93 ± 0.69	6.21 ± 0.26
sCT_{8-32}	8.52 ± 0.08	8.94 ± 0.04
AC187	8.62 ± 0.08	8.53 ± 0.05
AC413	8.59 ± 0.05	8.54 ± 0.06
$h\alpha CGRP_{8-37}$	7.56 ± 0.16	7.51 ± 0.16
rAMY ₈₋₃₇	=6	6.67 ± 1.06
hAM_{22-52}	<6	< 6

spectrum of agonist and antagonist behavior at AMY receptors that provides a potential explanation for CGRP₂ receptor pharmacology. The AMY_{1(a)} receptor is potently activated by CGRP and its analogs and antagonized weakly by CGRP₈₋₃₇, fitting in with the classic definition of the CGRP₂ receptor (Dennis et al., 1990, 1991). The AMY_{3(a)} receptor also has reasonable affinity for CGRP and is weakly antagonized by CGRP₈₋₃₇ but shows little stimulation by linear CGRP analogs. Nonetheless, because these latter analogs are rarely used, it may also contribute to reports of CGRP₂ receptors in the literature.

The actions of CGRP-derived agonists call for comment. Here, $(Cys(Acm)^{2,7})-\alpha CGRP$ and $(Cys(Et)^{2,7})-\alpha CGRP$ were partial agonists, in contrast to the data of Kuwasako et al. (2004). It is highly likely that this discrepancy may be explained by the human embryonic kidney 293 cells used by Kuwasako and colleagues having more efficient receptor coupling to G proteins, masking partial agonist behavior. In support of this, α CGRP was also much more potent in their study. It is also significant that Kuwasako et al. (2004) showed that there was relatively little difference in the dissociation constants for CGRP and the two Cys-modified analogs as measured in binding studies; a consistent theme in the literature has been the failure to observe a CGRP₁/ CGRP₂ difference using radioligand binding (Dennis et al., 1990). In the porcine aorta, $(Cys(Acm)^{2,7})$ - $\alpha CGRP$ was a partial agonist (Waugh et al., 1999).

In summary, despite the complicated pharmacology of CT/ RAMP complexes, there are several useful tools in defining these receptors including agonists (rAMY and hCT) that are specific for CT and AMY receptor subtypes and antagonists (sCT₈₋₃₂, AC187, and CGRP₈₋₃₇) that used in conjunction can help define these receptor classes. Individual receptor subtypes, such as AMY_{1(a)} and AMY_{3(a)} receptors, can also be discriminated with careful use of additional agonists such as the CGRPs. However, system-dependent factors such as coupling efficiency must also be considered. Finally, it is likely that most CGRP₂ receptor behavior can be attributed to existing CT/RAMP and CL/RAMP based receptors.

Acknowledgments

We thank Teddy Hsu for the providing IMDS and Andrew Young for AC413.

References

- Aiyar N, Baker E, Martin J, Patel A, Stadel JM, Willette RN, and Barone FC (1995) Differential calcitonin gene-related peptide (CGRP) and amylin binding sites in nucleus accumbens and lung: potential models for studying CGRP/amylin receptor subtypes. J Neurochem 65:1131-1138.
- Armour SL, Foord S, Kenakin T, and Chen WJ (1999) Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J Pharmacol Toxicol Methods 42:217–224.
- Bhogal R, Smith DM, Owji AA, and Bloom SR (1992) Binding sites for islet amyloid polypeptide in mammalian lung: species variation and effects on adenylyl cyclase. Can J Physiol Pharmacol 73:1030–1036.
- Brain SD and Grant AD (2004) Vascular actions of calcitonin gene-related peptide and adrenomedullin. *Physiol Rev* 84:903–934.
- Christopoulos A (1998) Assessing the distribution of parameters in models of ligandreceptor interaction: to log or not to log. *Trends Pharmacol Sci* **19**:351–357.
- Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, and Sexton PM (2003) Novel receptor partners and function of receptor activity-modifying proteins. *J Biol Chem* **278**:3293–3297. Christopoulos A and El-Fakahany EE (1999) Qualitative and quantitative assess-
- Christopoulos A and El-Fakahany EE (1999) Qualitative and quantitative assessment of relative agonist efficacy. *Biochem Pharmacol* 58:735-748.
- Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. *Pharmacol Rev* 54:323-374.
- Christopoulos G, Perry KJ, Morphis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, and Sexton PM (1999) Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. *Mol Pharmacol* 56:235–242.

Molecularly and Pharmacologically Distinct Amylin Receptors 1665

Cooper GJ (1994) Amylin compared with calcitonin gene-related peptide: structure, biology and relevance to metabolic disease. *Endocr Rev* 15:163-201.

- Dennis T, Fournier A, Cadieux A, Pomerleau F, Jolicoeur FB, St Pierre S, and Quirion R (1990) hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J Pharmacol Exp Ther 254:123-128.
- Dennis T, Fournier A, Guard S, St Pierre S, and Quirion R (1991) Calcitonin gene-related peptide (hCGRP alpha) binding sites in the nucleus accumbens. Atypical structural requirements and marked phylogenic differences. Brain Res 539:59-66.
- Findlay DM, deLuise M, Michelangeli VP, Ellison M, and Martin TJ (1980) Properties of a calcitonin receptor and adenylate cyclase in BEN cells, a human cancer cell line. *Cancer Res* 40:1311-1317.
- Hay DL, Conner AC, Howitt SG, Takhshid MA, Simms J, Mahmoud K, and Poyner DR (2004) The pharmacology of CGRP-responsive receptors in cultured and transfected cells. *Peptides* 25:2019–2026.
- Hay DL, Howitt SG, Conner AC, Schindler M, Smith DM, and Poyner DR (2003) CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors; a comparison of effects of adrenomedullin₂₂₋₅₂, CGRP₈₋₃₇ and BIBN4096BS. Br J Pharmacol 140:477-486.
- Hinson JP, Kapas S, and Smith DM (2000) AM, a multifunctional regulatory peptide. Endocr Rev 21:138–167.
- Howitt SG and Poyner DR (1997) The selectivity and structural determinants of peptide antagonists at the CGRP receptor of rat, L6 myocytes. Br J Pharmacol 121:1000-1004.
- Katafuchi T, Kikumoto K, Hamano K, Kangawa K, Matsuo H, and Minamino N (2003) Calcitonin receptor-stimulating peptide, a new member of the calcitonin gene-related peptide family. Its isolation from porcine brain, structure, tissue distribution and biological activity. J Biol Chem 278:12046-12054.
- Kenakin TP (1997) Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott-Raven, Philadelphia, PA.
- Kuestner RE, Elrod RD, Grant FJ, Hagen FS, Kuijper JL, Matthewes SL, O'Hara PJ, Sheppard PO, Stroop SD, and Thompson DL (1994) Cloning and characterization of an abundant subtype of the human calcitonin receptor. *Mol Pharmacol* 46:246– 255.
- Kuwasako K, Yuan-Ning C, Nagoshi Y, Tsuruda T, Kitamura K, and Eto T (2004) Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins. *Mol Pharmacol* 65:207–213.
- Leuthauser K, Gujer R, Aldecoa A, McKinney RA, Muff R, Fischer JA, and Born W (2000) Receptor-activity-modifying protein 1 forms heterodimers with two Gprotein-coupled receptors to define ligand recognition. *Biochem J* 351:347-351.
- Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gorn A, Kolakowski LF Jr, Lodish HF, and Goldring SR (1991) Expression cloning of an adenylate cyclasecoupled calcitonin receptor. *Science (Wash DC)* **254**:1022-1024.
- McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, and Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin receptor-like receptor. *Nature (Lond)* **393**:333–339.
- Motulsky HJ and Christopoulos A (2004) Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting. Oxford University Press, New York.

- Muff R, Bühlmann N, Fischer JA, and Born W (1999) An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. *Endocrinology* 140:2924–2927.
- Pham V, Wade J, Purdue B, and Sexton PM (2004) Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor. J Biol Chem 279:6720-6729.
- Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, and Foord SM (2002) International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin and calcitonin receptors. *Pharmacol Rev* 54:233-246.
- Roh J, Chang CL, Bhalla A, Klein C, and Hsu SY (2004) Intermedin is a calcitonin/ calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 279:7264–7274.
- Rorabaugh BR, Scofield MA, Smith DD, Jeffries WB, and Abel PW (2001) Functional calcitonin gene-related peptide subtype 2 receptors in porcine coronary arteries are identified as calcitonin gene-related peptide subtype 1 receptors by radioligand binding and reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther **299**:1086–1094.
- Sexton PM, Findlay DM, and Martin TJ (1999) Calcitonin. Curr Med Chem 6:1067– 1093.
- Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y, Imai Y, Ebihara A, Kuwaki T, Ju KH, et al. (2001) Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. *Circulation* 104:1964–1971.
- Takei Y, Hyodo S, Katafuchi T, and Minamino N (2004) Novel fish-derived adrenomedullin in mammals: structure and possible function. *Peptides* 25:1643– 1656.
- Tilakaratne N, Christopoulos G, Zumpe E, Foord SM, and Sexton PM (2000) Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 294:61–72.
- Wang ZL, Bennet WM, Ghatei MA, Byfield PG, Smith DM, and Bloom SR (1993) Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. *Diabetes* 42:330-335.
- Waugh DJ, Bockman CS, Smith DD, and Abel PW (1999) Limitations in using peptide drugs to characterize calcitonin gene-related peptide receptors. J Pharmacol Exp Ther 289:1419-1426.
- Ye JM, Lim-Fraser M, Cooney GJ, Cooper GJ, Iglesias MA, Watson DG, Choong B, and Kraegen EW (2001) Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance. Am J Physiol 280:E562–E569.
- Zumpe ET, Tilakaratne N, Fraser NJ, Christopoulos G, Foord SM, and Sexton PM (2000) Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. *Biochem Biophys Res Commun* **267**:368–372.

Address correspondence to: Dr. Patrick M. Sexton, Howard Florey Institute, University of Melbourne, Victoria 3010, Australia. E-mail: p.sexton@hfi. unimelb.edu.au